ECTRIMS eLearning

Clinical presentation of Anti MOG seropositivity in Israel
Author(s): ,
L. Brill
Affiliations:
Department of Neurology & Laboratory of Neuroimmunology, Hadassah Hebrew University Medical Center, Jerusalem in Israel | Neurology, Hadassah- Medical Center
A. Vaknin Dembinsky
Affiliations:
Department of Neurology & Laboratory of Neuroimmunology, Hadassah Hebrew University Medical Center, Jerusalem in Israel | Neurology, Hadassah - Medical Center, Jerusalem, Israel
ECTRIMS Learn. Vaknin Dembinsky A. 10/11/18; 228507; P663
Adi Vaknin Dembinsky
Adi Vaknin Dembinsky
Contributions
Abstract

Abstract: P663

Type: Poster Sessions

Abstract Category: Clinical aspects of MS - MS Variants

Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been recently recognized as a new inflammatory, demyelinating disease of the central nervous system (CNS). The antibodies are found mostly in patients with aquaporin-4 antibody (AQP4-IgG) sero-negative neuromyelitis optica spectrum disorders (NMOSD) and in ADEM patients. however, disease course and disability outcomes of those patients are largely unknown.
Study aim: to investigated the clinical and para clinical characteristics of MOG- antibody disease in Israel.
Methods: MOG antibodies were detected in serum using cell-based assay, and clinical data were collected from the patients' files.
Results: Of 146 patients with NMOSD or ADEM like presentation tested for anti MOG antibodies between 2017-2018 at the Hadassah neurology department, 14 were positive (9.6%). Nine female and 5 males, average age 18±11.7Y. Among the NMO like syndrome 3 patients had a monophasic optic neuritis, 7 had bilateral or recurrent optic neuritis, and myelitis was in 2 patients. One patient had an encephalitis with status epilepticus. Two patients had ADEM like presentation.
Nine of 14 positive patients (64%) were under 18 years compared to 46 out of 132 negative patients (35%) (P˂0.01).
Conclusions: the syndrome of MOG-IgG is a relatively new autoimmune disease. We observed in our cohort a significantly higher prevalence in young individuals, highlight the need for repeated evaluation of MOG-IgG in this age group of patients with CNS demyelination.
Disclosure: Livnat Brill: nothing to disclose
Adi Vaknin Dembinsky: : nothing to disclose

Abstract: P663

Type: Poster Sessions

Abstract Category: Clinical aspects of MS - MS Variants

Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been recently recognized as a new inflammatory, demyelinating disease of the central nervous system (CNS). The antibodies are found mostly in patients with aquaporin-4 antibody (AQP4-IgG) sero-negative neuromyelitis optica spectrum disorders (NMOSD) and in ADEM patients. however, disease course and disability outcomes of those patients are largely unknown.
Study aim: to investigated the clinical and para clinical characteristics of MOG- antibody disease in Israel.
Methods: MOG antibodies were detected in serum using cell-based assay, and clinical data were collected from the patients' files.
Results: Of 146 patients with NMOSD or ADEM like presentation tested for anti MOG antibodies between 2017-2018 at the Hadassah neurology department, 14 were positive (9.6%). Nine female and 5 males, average age 18±11.7Y. Among the NMO like syndrome 3 patients had a monophasic optic neuritis, 7 had bilateral or recurrent optic neuritis, and myelitis was in 2 patients. One patient had an encephalitis with status epilepticus. Two patients had ADEM like presentation.
Nine of 14 positive patients (64%) were under 18 years compared to 46 out of 132 negative patients (35%) (P˂0.01).
Conclusions: the syndrome of MOG-IgG is a relatively new autoimmune disease. We observed in our cohort a significantly higher prevalence in young individuals, highlight the need for repeated evaluation of MOG-IgG in this age group of patients with CNS demyelination.
Disclosure: Livnat Brill: nothing to disclose
Adi Vaknin Dembinsky: : nothing to disclose

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies